Literature DB >> 18443964

Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer.

Seung-Su Han1, Sung Ho Choi, Yoo-Kyung Lee, Jae Weon Kim, Noh-Hyun Park, Yong-Sang Song, Hyo-Pyo Lee, Soon-Beom Kang.   

Abstract

The aim of this study is to investigate the correlation between ATP-based chemotherapy response assay (ATP-CRA) results and clinical outcomes in ovarian cancer. Twenty-nine fresh tumor specimens were collected. Tumor cells were isolated and cultured for 48 hrs in medium containing anticancer drugs. The median age of patients was 56 years. The sensitivity, positive predictive value, and accuracy of ATP-CRA were respectively 94.1%, 94.1%, and 90.0%. There was a significant relationship between ATP-CRA results and clinical responses (p = 0.046). This study suggests that ATP-CRA has high sensitivity, positive predictive value, and accuracy for predicting response to chemotherapy in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443964     DOI: 10.1080/07357900701813250

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  9 in total

Review 1.  Recent applications of chemosensitivity tests for colorectal cancer treatment.

Authors:  Yong Sik Yoon; Jin Cheon Kim
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

2.  Individualized tumor response testing for prediction of response to Paclitaxel and Cisplatin chemotherapy in patients with advanced gastric cancer.

Authors:  Jee Hyun Kim; Keun-Wook Lee; Yeul Hong Kim; Kyung Hee Lee; Do Youn Oh; Joonhee Kim; Sung Hyun Yang; Seock-Ah Im; Sung Ho Choi; Yung-Jue Bang
Journal:  J Korean Med Sci       Date:  2010-04-21       Impact factor: 2.153

3.  Predictive value of in vitro adenosine triphosphate-based chemotherapy response assay in advanced gastric cancer patients who received oral 5-Fluorouracil after curative resection.

Authors:  Ji Hyun Lee; Min-Chan Kim; Sung Yong Oh; Hyuk-Chan Kwon; Sung-Hyun Kim; Kyung A Kwon; Suee Lee; Jin Sook Jeong; Seok-Reyol Choi; Hyo-Jin Kim
Journal:  Cancer Res Treat       Date:  2011-06-30       Impact factor: 4.679

4.  Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis.

Authors:  H Hur; N K Kim; H G Kim; B S Min; K Y Lee; S J Shin; J H Cheon; S H Choi
Journal:  Br J Cancer       Date:  2011-11-08       Impact factor: 7.640

5.  Innovative in vitro chemo-hormonal drug therapy for refractory thyroid carcinomas.

Authors:  Tae-Yon Sung; Sung Ho Choi; Jung Min Lee; Jong Ju Jeong; Sang-Wook Kang; Woong Youn Chung
Journal:  J Korean Med Sci       Date:  2012-06-29       Impact factor: 2.153

6.  ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.

Authors:  Maria Lee; Sang Wun Kim; Eun Ji Nam; Hanbyoul Cho; Jae Hoon Kim; Young Tae Kim; Sunghoon Kim
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

7.  Identification of proteins associated with paclitaxel resistance of epithelial ovarian cancer using iTRAQ-based proteomics.

Authors:  Yuanjing Wang; Hongxia Li
Journal:  Oncol Lett       Date:  2018-04-27       Impact factor: 2.967

Review 8.  Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept.

Authors:  Christophe Bounaix Morand du Puch; Mathieu Vanderstraete; Stéphanie Giraud; Christophe Lautrette; Niki Christou; Muriel Mathonnet
Journal:  Theranostics       Date:  2021-09-21       Impact factor: 11.556

9.  Clinical value of an adenosine triphosphate-based chemotherapy response assay in resectable stage III colorectal cancer.

Authors:  Chan Dong Kim; So Hyun Kim; Sang Hoon Jung; Jae Hwang Kim
Journal:  Ann Surg Treat Res       Date:  2019-07-29       Impact factor: 1.859

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.